Market Access News | pharmaphorum

News

Vivek Ramaswamy exits presidential race after Iowa result

Biotech entrepreneur Vivek Ramaswamy’s campaign to become the Republican candidate for the US presidency in the 2024 election has been suspended after a disappointing resu

News

Keytruda breaks new ground in cervical cancer

MSD’s checkpoint inhibitor Keytruda has been cleared by the FDA for use in newly diagnosed cervical cancer patients with less severe disease, becoming the first anti-PD-1/

News

FDA finds no link between GLP-1 drugs and suicide

The FDA has given an update on its ongoing review of a possible link between GLP-1 agonist drugs used to treat diabetes and obesity and suicide, saying it can find no evid

News

FDA starts review of Lantheus’ generic Lutathera

Lantheus has filed what it says is the first generic version of Novartis’ big-selling cancer radionuclide therapy Lutathera in the US, used to treat rare neuroendocrine tu

News

NICE expands access to Paxlovid amid over-supply

NICE has extended the number of patients eligible for treatment with Pfizer’s oral antiviral Paxlovid by around 1.4 million, as millions of doses of the COVID-19 therapy a

News

FDA clears French syphilis drug imports to tackle shortage

Facing a sharp rise in the number of syphilis cases, the FDA has authorised the importation from France of a life-saving drug for the sexually transmitted infection (STI)

Vivek Ramaswamy exits presidential race after Iowa result

Keytruda breaks new ground in cervical cancer

FDA finds no link between GLP-1 drugs and suicide

FDA starts review of Lantheus’ generic Lutathera

NICE expands access to Paxlovid amid over-supply

FDA clears French syphilis drug imports to tackle shortage

Hims & Hers to offer unapproved peptides to customers

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks